AstraZeneca Showcases the P-III (ECHO) Study Data of Calquence Combination Regimen for Mantle Cell Lymphoma at EHA 2024
Shots:
- ECHO study investigates the safety & efficacy of Calquence + bendamustine + rituximab vs SoC (bendamustine + rituximab) in treatment-naïve MCL patients (n=635, over 65yrs.)
- The study depicted a 27% reduction in the disease progression or death risk with an mPFS of 66.4mos. vs 49.6mos. (n=299 in each arm). The OS data (2EP) was immature with favourable trends observed
- In the pre-specified analysis, carried out at the time of pandemic censoring COVID-19-related deaths, showed improved PFS of 36% across both arms with mPFS not attained vs 61.6mos. and a favourable OS trend towards the regimen
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Reports Data from the P-III (ECHO) Study of Calquence Combination Regimen for Mantle Cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
